Psychedelic drug contenders suffer stock drops after FDA rejects MDMA treatment

Shares of companies developing treatments based on psilocybin and other psychedelic drugs fell on Monday after the US Food and Drug Administration rejected the use of MDMA for post-traumatic stress disorder.